Briacell Therapeutics Corp. Common Shares
Symbol: BCTX (NASDAQ)
12.02
▼ (-5.87%) -0.750
Company Description:
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
Key Stats
- Today's Open: $12.9
- Today's High: $13.602
- Today's Low: $11.825
- Today's Volume: 117.68K
- Yesterday Close: $12.77
- Yesterday High: $14.68
- Yesterday Low: $12.31
- Yesterday Volume: 478.71K
- Last Min Volume: 202
- Last Min High: $12.039
- Last Min Low: $12
- Last Min VWAP: $12.00712
Company Profile
- Name: Briacell Therapeutics Corp. Common Shares
- Website: https://www.briacell.com
- Listed Date: 2023-09-05
- Location: WEST VANCOUVER, A1
- Market Status: Active
- CIK Number: 0001610820
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $22.87M
- Round Lot: 100
- Outstanding Shares: 1.88M
- Asset Type: CS
RECENT FILINGS FOR BCTX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-16 | 10-K | View |
| 2025-10-10 | SCHEDULE 13G | View |
| 2025-08-26 | 8-K | View |
| 2025-08-01 | S-8 | View |
| 2025-07-28 | SCHEDULE 13G | View |
| 2025-07-22 | SCHEDULE 13G | View |
| 2025-07-21 | SCHEDULE 13G/A | View |
| 2025-07-16 | 8-K | View |
| 2025-07-16 | 424B4 | View |
| 2025-07-15 | EFFECT | View |
| 2025-07-15 | CORRESP | View |
| 2025-07-15 | CORRESP | View |
| 2025-07-14 | CORRESP | View |
| 2025-07-14 | CORRESP | View |
| 2025-07-11 | CORRESP | View |
| 2025-07-11 | CORRESP | View |
| 2025-07-11 | FWP | View |
| 2025-07-10 | S-1/A | View |
| 2025-07-09 | S-1/A | View |
| 2025-07-08 | FWP | View |
Latest News on BCTX